{"id":39200,"date":"2017-05-22T07:16:45","date_gmt":"2017-05-22T11:16:45","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=39200"},"modified":"2017-05-22T07:16:59","modified_gmt":"2017-05-22T11:16:59","slug":"immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200","title":{"rendered":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients"},"content":{"rendered":"<p style=\"text-align: justify;\">The most recent results from the mid-stage trial by <strong>ImmunoGen, Inc <\/strong><strong>(NASDAQ:IMGN) <\/strong>have brought about a new revelation. It had of course put under trial the experimental antibody-drug conjugate\u00a0and it was discovered that it showcases remarkable abilities when it comes to shrinking or on the other hand stabilizing tumors in nearly half of advanced ovarian cancer patients. This is of course in reference to the least medium levels of a main biomarker whose state has proven resistant to the standard chemotherapy.<\/p>\n<p style=\"text-align: justify;\">A much closer scrutiny at about some 113 patients\u00a0that have so far been evaluated in line with the trial indicates that about 30 percent of them showcased better responses. Some of the top trusted sources went ahead to actually indicate that a number of them lived for a median of 4.3 months\u00a0without their condition worsening.<\/p>\n<p style=\"text-align: justify;\">The pivotal trial to be undertaken will indeed be a great move. The provider is said to be enrolling patients selectively. Hopefully by 2019, the provider is looking forward to have reached its goal of actually obtaining final sets of data from the trial. After that, the company\u2019s board of directors hopes to delve into the markets as quickly as possible.<\/p>\n<p style=\"text-align: justify;\">Let\u2019s face it once and for all. Almost 22,400 American women every year get diagnosed with ovarian cancer and it goes without saying that this is actually a large number which indicates that we risk losing a lot of lives through the condition every year. From statistics, 14,000 eventually lose their lives and the American Cancer Society thinks that something needs to be done.<\/p>\n<p style=\"text-align: justify;\">Mirvetuximab soravtansine as a matter of fact works with an anti-tumor agent in a move to destroy the targeted cells. ImmunoGen has also been making efforts to delve into a study that will enable it research further on a drug combination as well a wide range of some other treatments targeting the earlier-stage ovarian cancer.<\/p>\n<p style=\"text-align: justify;\">It goes without saying that there is great need to actually engage in more advanced combination trials\u00a0in a bid to ensure that the various patients around the globe get to enjoy the very best in terms of treatments and top remedies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The most recent results from the mid-stage trial by ImmunoGen, Inc (NASDAQ:IMGN) have brought about a new revelation. It had of course put under trial [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":39205,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12659,1764,1765],"stock_ticker":[],"class_list":["post-39200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-immunogen-inc","tag-immunogen-inc-nasdaqimgn","tag-nasdaqimgn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The most recent results from the mid-stage trial by ImmunoGen, Inc (NASDAQ:IMGN) have brought about a new revelation. It had of course put under trial [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-22T11:16:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-05-22T11:16:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"5120\" \/>\n\t<meta property=\"og:image:height\" content=\"3413\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients\",\"datePublished\":\"2017-05-22T11:16:45+00:00\",\"dateModified\":\"2017-05-22T11:16:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg\",\"keywords\":[\"ImmunoGen Inc\",\"ImmunoGen Inc (NASDAQ:IMGN)\",\"NASDAQ:IMGN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\",\"name\":\"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg\",\"datePublished\":\"2017-05-22T11:16:45+00:00\",\"dateModified\":\"2017-05-22T11:16:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg\",\"width\":5120,\"height\":3413},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200","og_locale":"en_US","og_type":"article","og_title":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR","og_description":"The most recent results from the mid-stage trial by ImmunoGen, Inc (NASDAQ:IMGN) have brought about a new revelation. It had of course put under trial [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-05-22T11:16:45+00:00","article_modified_time":"2017-05-22T11:16:59+00:00","og_image":[{"width":5120,"height":3413,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients","datePublished":"2017-05-22T11:16:45+00:00","dateModified":"2017-05-22T11:16:59+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg","keywords":["ImmunoGen Inc","ImmunoGen Inc (NASDAQ:IMGN)","NASDAQ:IMGN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200","url":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200","name":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg","datePublished":"2017-05-22T11:16:45+00:00","dateModified":"2017-05-22T11:16:59+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/05\/39204-new-york-wall-street.jpg","width":5120,"height":3413},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-engages-in-numerous-drug-combinations-in-a-bid-to-offer-the-best-treatment-to-the-ovarian-cancer-patients-39200#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"ImmunoGen, Inc (NASDAQ:IMGN) Engages In Numerous Drug Combinations In A Bid To Offer The Best Treatment To The Ovarian Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=39200"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39200\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/39205"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=39200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=39200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=39200"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=39200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}